# Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)

> **NCT06489028** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **RHEACELL GmbH & Co. KG** · enrollment: 250 (estimated)

## Conditions studied

- Venous Leg Ulcer

## Interventions

- **DRUG:** allo-APZ2-CVU
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06489028
- **Lead sponsor:** RHEACELL GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-26
- **Primary completion:** 2027-04
- **Final completion:** 2027-09
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06489028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06489028, "Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06489028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*